5th Antiviral Research & Development
This conference will bring together an exciting balance of industry and academia, where drug and vaccine designs in HIV, RSV, Hepatitis B/C, Influenza, etc. will be discussed. Top researchers will share their experiences with new inhibitory mechanisms, longer acting drugs, and strategies en route for cures. Delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the research in antiviral drugs.
2nd Bugs & Drugs: Antibacterial Drug Discovery
The increase and spread of antibiotic-resistance and the reduced investment by the pharmaceutical industry have given us an unsettling glimpse of a post-antibiotic era. Ultimately, it is the goal of the scientific community, and certainly that of the attendees, to forestall that event and to prevent the serious consequences that would come inevitably from it.
14th Vaccines Research & Development
Newly emerging infections have opened up dialogue about the need for novel treatments and government response to such infections. As we continue to search for solutions, we must review the lessons learned from research and industry response in order to overcome the current challenges. There are a number of exciting new developments including traditional vaccines and application of vaccines to new diseases, such as cancer vaccines. We will also discuss innovative efficacy trials and how to accelerate vaccine development. Join us as colleagues from industry and academia gather to discuss newly licensed vaccines, new vaccine technologies, RNA-based vaccines, and adjuvant discovery.
13th Anti-Infectives Partnering & Deal-Making
Over the years, the anti-Infectives field has faced the same challenges in areas such as pricing and reimbursement and overcoming resistance in diseases. However, drug approvals over the past year and President Obama's recent proposal to spend $1.2 billion to address antimicrobial resistance are indications that the field is still changing and evolving.